Pasar al contenido principal
Inicio

Dedicated to discovery

  • Acerca de ELGA
    • Acerca de ELGA
    • Empleo
    • Eventos
  • Soporte
    • Planificación de laboratorio
  • Contacto
  • EN
  • DE
  • FR
  • IT
  • PT
  • EN-US
Inicio
  • Productos
    • PURELAB
      • PURELAB® Dispenser
      • PURELAB® Flex
      • PURELAB® Quest
      • PURELAB® Pharma Compliance
      • PURELAB® Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB® Chorus 2
      • PURELAB® Chorus 3
      • Purelab Chorus 2+ (RO/DI/UV) / (RO/EDI/UV)
    • CENTRA
      • CENTRA® R60/120
      • CENTRA® R200
      • CENTRA® RDS
    • MEDICA
      • MEDICA® 150
      • MEDICA® 7/15
      • MEDICA® BIOX 2024
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
      • MEDICA® EDI 15/30
      • MEDICA® Pro-LPS
      • MEDICA® Pro EDI 60/120
      • MEDICA® BIOX
      • Hubgrade
    • BIOPURE
      • BIOPURE® 300/600
    • PURENERGY® 30
    • Gama completa de productos ELGA
  • Aplicaciones
    • Análisis microbiológico
    • Bioquímica clínica
    • Cromatografía de gases
    • Cromatografía líquida
      • High Performance Liquid Chromatography
    • Cultivos celulares
    • Electroquímica
    • Espectrofotometría
    • Espectrometría de masas
    • Espectroscopia atómica
    • Genética
    • High Performance Liquid Chromatography (HPLC)
    • Inmunoquímica
    • Requisitos generales de agua de laboratorio
  • Tecnologías
    • Carbón activado
    • Electrodesionización (EDI)
    • Filtración
    • Intercambio iónico
    • PureSure
    • Ultravioleta
    • Ósmosis inversa
  • Impurezas en el agua
    • Compuestos inorgánicos
    • Compuestos orgánicos
    • Gases disueltos
    • Microorganismos y bacterias
    • Partículas
  • Conocimiento
    • BROSCHÜREN
    • Blog
    • Casos prácticos
    • Agua ultrapura
    • Manuales e informes técnicos
  • Where to buy
  • Contacto
Home
  • Contacto
  • Productos
    • PURELAB
      • PURELAB® Dispenser
      • PURELAB® Flex
      • PURELAB® Quest
      • PURELAB® Pharma Compliance
      • PURELAB® Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB® Chorus 2
      • PURELAB® Chorus 3
      • Purelab Chorus 2+ (RO/DI/UV) / (RO/EDI/UV)
    • CENTRA
      • CENTRA® R60/120
      • CENTRA® R200
      • CENTRA® RDS
    • MEDICA
      • MEDICA® 150
      • MEDICA® 7/15
      • MEDICA® BIOX 2024
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
      • MEDICA® EDI 15/30
      • MEDICA® Pro-LPS
      • MEDICA® Pro EDI 60/120
      • MEDICA® BIOX
      • Hubgrade
    • BIOPURE
      • BIOPURE® 300/600
    • PURENERGY® 30
    • Gama completa de productos ELGA
  • Aplicaciones
    • Análisis microbiológico
    • Bioquímica clínica
    • Cromatografía de gases
    • Cromatografía líquida
      • High Performance Liquid Chromatography
    • Cultivos celulares
    • Electroquímica
    • Espectrofotometría
    • Espectrometría de masas
    • Espectroscopia atómica
    • Genética
    • High Performance Liquid Chromatography (HPLC)
    • Inmunoquímica
    • Requisitos generales de agua de laboratorio
  • Tecnologías
    • Carbón activado
    • Electrodesionización (EDI)
    • Filtración
    • Intercambio iónico
    • PureSure
    • Ultravioleta
    • Ósmosis inversa
  • Impurezas en el agua
    • Compuestos inorgánicos
    • Compuestos orgánicos
    • Gases disueltos
    • Microorganismos y bacterias
    • Partículas
  • Conocimiento
    • BROSCHÜREN
    • Blog
    • Casos prácticos
    • Agua ultrapura
    • Manuales e informes técnicos
  • Where to buy
  • Contacto
  • Acerca de ELGA
    • Acerca de ELGA
    • Empleo
    • Eventos
  • Soporte
    • Planificación de laboratorio
  • Contacto
  • EN
  • DE
  • FR
  • IT
  • PT
  • EN-US
  • Política de privacidad
  • Términos y condiciones
  • Cumplimiento legal internacional
  • Patentes
  • Trademarks
  • Aviso legal
  • Can Clay Help Control The Release Of Drugs For Treating Alzheimer’s Disease?
Clinical & Pharma
Science of the Future

Can Clay Help Control The Release Of Drugs For Treating Alzheimer’s Disease?

1 Jun 2020
- by Dr Alison Halliday

Senior marriage sitting on the sofa and looking at old photos

A new study demonstrates the potential of clay-based nanocarrier systems for improving the oral delivery of drugs to treat the most common type of dementia.

Almost 47 million people worldwide are living with dementia – and predictions suggest that these numbers will double every 20 years. Alzheimer’s disease is by far the most common type, accounting for about two-thirds of cases in older people. A person will experience problems affecting their memory, communication and other cognitive abilities.

Sadly, there is no cure for Alzheimer’s disease – and a person’s symptoms will get progressively worse over time. But medications are currently available that may help reduce some symptoms and maximise a person’s quality of life for as long as possible. Our increased understanding of the biology of the disease is also fuelling the development of a wave of new targeted drugs that aim to slow down or stop the progression of the disease.

But developing drug formulations that are easy to take – and can deliver and maintain safe and effective doses within the body – poses challenges for researchers.

Challenges With Oral Formulations

Drugs that can be taken by mouth – for example, as pills or capsules – are usually preferred by patients. But the drug will often be rapidly released into the body – leading to short-lived high levels in the bloodstream followed by a sharp fall. So a patient would need to take regular doses, increasing their risk of side effects.

Scientists are aiming to develop innovative oral drug delivery systems that can help maintain constant and effective levels over long periods with a single dose. Clay minerals offer promise as materials for these drug carriers as they are inert, non-toxic, and may also have properties that help induce the release of the active ingredient.

Encapsulated Clay-Based Nanocarriers

In a new study, published in Applied Clay Science, researchers explore the potential of clay-based nanocarriers for the controlled release of orally administered neuroprotective drugs in the treatment of Alzheimer’s disease.1

The team developed four systems based on two clay minerals (montmorillonite and halloysite) and two potential drugs for treating Alzheimer’s disease. They then tested their effects on human nerve cells grown in the laboratory – showing that they can protect them from damage in a similar manner to pure drugs. However, the team found that drug release occurred very quickly in a simulated gastrointestinal tract.

The researchers then added a biopolymer coating – a blend of alginate from brown algae and the corn protein zein – and showed that alginate–zein@7-azaindole derivate/halloysite nanocomposite beads exhibited controlled drug release along the entire simulated gastrointestinal tract. The team used ultrapure water generated from an ELGA in–house laboratory water purification system to reduce the risk of adding contaminants that may affect their results.

Better For Patients

The study suggests that clay-based drug delivery systems with biopolymer coatings offer a promising route for improving the controlled oral delivery of potential new drugs for Alzheimer’s disease. These innovative new drug formulations could help improve the effectiveness of treatment while reducing side effects for patients.

Why Choose ELGA LabWater?

ELGA has been a trusted name in pure and ultrapure water since 1937. Our dedication to ultrapure and pure water is a guarantee that we will continue to provide the best solutions with the best service.


Reference:
Garcia–Vazquez R. et al. Clay-based hybrids for controlled release of 7–azaindole derivatives as neuroprotective drugs in the treatment of Alzheimer’s disease. Applied Clay Science 2020; 189: 105541 


Dr Alison Halliday
After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

  • Sales Enquiry
  • Consigue una cotización
  • Technical Support
  • Encuentre un socio aprobado

Sales Enquiry

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

I'd like to receive updates from ELGA LabWater & ELGA Approved Partners based on my details.

Consigue una cotización

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

I'd like to receive updates from ELGA LabWater & ELGA Approved Partners based on my details.

Technical Support

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

Sede central de ELGA LabWater

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
Reino Unido
Tel.: +44 (0) 203 567 7300
F: +44 (0) 203 567 7205

Casos prácticos

  • Abbott Diagnostics
  • Diagnóstico médico de DASA
  • Instituto Médico NeoDIN
  • Fundación del NHS de North Staffordshire
  • Escuela técnica de Olsberg

Recursos

  • Obtenga más información sobre el agua ultrapura
  • Manuales e informes técnicos
  • Tecnologías de purificación
  • Aplicaciones
  • Impurezas en el agua
  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?

© VWS (UK) Ltd. comercializado como ELGA LabWater.2025-Todos los derechos reservados.
ELGA es la marca mundial de agua de laboratorio de Veolia.

  • Política de privacidad
  • Términos y condiciones
  • Cumplimiento legal internacional
  • Patentes
  • Trademarks
  • Aviso legal
  • Idioma
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Otros sitios de Veolia
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies
Elga Veolia
TOP

© 2017 ELGA Veolia